Spots Global Cancer Trial Database for generalized myasthenia gravis
Every month we try and update this database with for generalized myasthenia gravis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | NCT05644561 | Generalized Mya... gMG | Ravulizumab | - | Alexion Pharmaceuticals, Inc. | |
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | NCT05644561 | Generalized Mya... gMG | Ravulizumab | - | Alexion Pharmaceuticals, Inc. | |
| Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | NCT05067348 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis | NCT04818671 | Generalized Mya... | efgartigimod PH... | 18 Years - | argenx | |
| Efgartigimod Expanded Access for Generalized Myasthenia Gravis | NCT04777734 | Generalized Mya... | efgartigimod | 18 Years - | argenx | |
| A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | NCT03971422 | Generalized Mya... | Rozanolixizumab Placebo | 18 Years - | UCB Pharma | |
| An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | NCT06435312 | Generalized Mya... | Zilucoplan | 12 Years - | UCB Pharma | |
| An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors | NCT05514873 | Generalized Mya... | zilucoplan (RA1... | 18 Years - 85 Years | UCB Pharma | |
| Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | NCT05218096 | Generalized Mya... Myasthenia Grav... | ALXN2050 Placebo | 18 Years - 130 Years | Alexion Pharmaceuticals, Inc. | |
| Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis | NCT05067348 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis | NCT06193889 | Myasthenia Grav... Generalized Mya... | KYV-101 Standard lympho... | 18 Years - 75 Years | Kyverna Therapeutics | |
| Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | NCT05218096 | Generalized Mya... Myasthenia Grav... | ALXN2050 Placebo | 18 Years - 130 Years | Alexion Pharmaceuticals, Inc. | |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | NCT06055959 | Generalized Mya... | Zilucoplan | 12 Years - 17 Years | UCB Pharma | |
| Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis | NCT04982289 | Generalized Mya... | ALXN1830 Placebo | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | NCT04124965 | Generalized Mya... | Rozanolixizumab | 18 Years - | UCB Pharma | |
| Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis | NCT04225871 | Generalized Mya... | zilucoplan (RA1... | 18 Years - | UCB Pharma | |
| A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG) | NCT05681715 | Generalized Mya... | Rozanolixizumab | 18 Years - | UCB Pharma | |
| Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | NCT04833894 | Generalized Mya... | Efgartigimod IV | 2 Years - 18 Years | argenx | |
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | NCT03920293 | Generalized Mya... | Ravulizumab Placebo | - | Alexion Pharmaceuticals, Inc. | |
| The Impact of Myasthenia Gravis in the Real World | NCT04176211 | Myasthenia Grav... | 18 Years - | Vitaccess Ltd | ||
| Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis | NCT00515450 | Generalized Mya... | GB-0998 (Intrav... Plasmapheresis | 16 Years - | Benesis Corporation | |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | NCT04202341 | Generalized Mya... | - | Alexion Pharmaceuticals, Inc. | ||
| Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis | NCT04818671 | Generalized Mya... | efgartigimod PH... | 18 Years - | argenx | |
| Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis | NCT04982289 | Generalized Mya... | ALXN1830 Placebo | 18 Years - | Alexion Pharmaceuticals, Inc. | |
| Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis | NCT03315130 | Generalized Mya... | zilucoplan (RA1... Placebo | 18 Years - 85 Years | UCB Pharma | |
| A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | NCT06149559 | Generalized Mya... | rozanolixizumab | 2 Years - 17 Years | UCB Pharma | |
| The Impact of Myasthenia Gravis in the Real World | NCT04176211 | Myasthenia Grav... | 18 Years - | Vitaccess Ltd | ||
| A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | NCT04650854 | Generalized Mya... | Rozanolixizumab | 18 Years - | UCB Pharma | |
| Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis | NCT05374590 | Generalized Mya... | Efgartigimod IV... | 2 Years - 18 Years | argenx | |
| Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis | NCT06371040 | Myasthenia Grav... | CD19-BCMA Targe... CD19-BCMA Targe... CD19-BCMA Targe... | 18 Years - 80 Years | Tang-Du Hospital | |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | NCT04146051 | Myasthenia Grav... | Descartes-08 | 18 Years - | Cartesian Therapeutics | |
| A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis | NCT06193889 | Myasthenia Grav... Generalized Mya... | KYV-101 Standard lympho... | 18 Years - 75 Years | Kyverna Therapeutics | |
| Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | NCT05403541 | Generalized Mya... | Batoclimab 680 ... Batoclimab 340 ... Matching Placeb... Batoclimab 340 ... | 18 Years - | Immunovant Sciences GmbH | |
| Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis | NCT06371040 | Myasthenia Grav... | CD19-BCMA Targe... CD19-BCMA Targe... CD19-BCMA Targe... | 18 Years - 80 Years | Tang-Du Hospital | |
| An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | NCT03669588 | Generalized Mya... | ARGX-113 Placebo | 18 Years - | argenx | |
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | NCT03920293 | Generalized Mya... | Ravulizumab Placebo | - | Alexion Pharmaceuticals, Inc. | |
| Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | NCT05403541 | Generalized Mya... | Batoclimab 680 ... Batoclimab 340 ... Matching Placeb... Batoclimab 340 ... | 18 Years - | Immunovant Sciences GmbH | |
| A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis | NCT04963270 | Generalized Mya... | Satralizumab Placebo | 12 Years - | Hoffmann-La Roche | |
| Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis | NCT05716035 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | NCT06055959 | Generalized Mya... | Zilucoplan | 12 Years - 17 Years | UCB Pharma | |
| Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis | NCT05716035 | Myasthenia Grav... | Tocilizumab Inj... | 18 Years - 80 Years | Tang-Du Hospital | |
| A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis | NCT06149559 | Generalized Mya... | rozanolixizumab | 2 Years - 17 Years | UCB Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
